Randox's Cardiac Array biochip combines the gold standard marker troponin with novel early markers such as FABP to enable an early myocardial infarction assessment at 3-6 hours after a coronary event
Biochip array technology allows multiple simultaneous results from a single patient sample, minimising biological variation and resulting in a more rapid and accurate diagnosis.
Based on Elisa principles, separate tests for a disease state, in this case cardiovascular disease, are spotted at discrete test regions on the surface of the biochip, allowing simultaneous multiple results from one small patient sample.
The Cardiac Array biochip was found to be 90% sensitive for the diagnosis of MI as early as three hours following a cardiac event.
It also enables acute coronary syndrome risk assessment and is a good rule-out marker panel with a negative predictive value of 97%.
The Cardiac Array from Randox presents a valuable assessment tool for the diagnosis of MI in an accident and emergency setting.
Randox is an international diagnostics company, headquartered in the UK.
Randox develops, manufactures and markets clinical diagnostic products worldwide.
Core products are: Biochip Array Technology; clinical chemistry analysers and reagents; quality controls and EQA; environmental diagnostics; recombinant proteins and antibodies.
